Core Viewpoint - BrainsWay Ltd. has announced that Premera Blue Cross Blue Shield has adopted a new medical policy expanding coverage for patients aged 15 and older with moderate to severe major depressive disorder treated with BrainsWay's SWIFT Deep TMS protocol, marking a significant development in insurance coverage for this treatment [1][2]. Group 1: Company Developments - The SWIFT depression protocol consists of five treatment sessions per day for six days, followed by two sessions per day once a week for four weeks, totaling 38 sessions, and does not require expensive neuronavigational equipment [3]. - BrainsWay's clinical trials and real-world evidence show comparable response and remission outcomes for the SWIFT protocol compared to the standard Deep TMS protocol, indicating its effectiveness [4]. - The company continues to lead in the field with its proprietary H-coil technology and is focused on expanding access to advanced neurostimulation therapies through collaboration with providers and policymakers [5]. Group 2: Company Background - BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, with a proprietary Deep TMS platform that has received FDA clearance for multiple indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [6]. - The company was founded in 2003 and operates in the United States and Israel, with ongoing clinical trials for various psychiatric, neurological, and addiction disorders [6].

Core Insights - AngioDynamics reported a Q2 2026 EPS of -$0.15, missing the estimated -$0.10, but exceeded revenue expectations with $79.43 million compared to the estimated $76.7 million [1][6] - The company experienced double-digit growth in its medical technology segment, contributing to increased profitability despite a negative P/E ratio of approximately -14.67 [2][6] - AngioDynamics raised its fiscal year 2026 adjusted EPS guidance, indicating a positive outlook for future performance, although shares declined by 1.8% to close at $12.87 [4][6] Financial Performance - Analysts had forecasted a quarterly loss of 10 cents per share, which is deeper than the 4 cents per share loss from the same quarter last year [3] - Revenue of $79.43 million surpassed the previous year's $72.84 million, indicating a positive trend in sales [3] - The company's price-to-sales ratio of about 1.56 suggests that investors are paying $1.56 for every dollar of sales, reflecting confidence in its revenue-generating capabilities [3] Analyst Sentiment - Canaccord Genuity analyst William Plovanic maintained a Buy rating and increased the price target from $17 to $18, indicating positive sentiment from analysts regarding the company's potential [4] - Despite financial challenges, the company maintains a strong current ratio of about 2.29, suggesting solid ability to cover short-term liabilities with short-term assets [5]

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, Baxter's president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers h ...

On Tuesday, William Blair upgraded Medtronic Plc (NYSE:MDT) , citing several new and ramping launches.William Blair upgraded from Market Perform to Outperform. Analyst Brandon Vazquez wrote that the Market Perform rating hinged on a business that was too large and not differentiated enough to durably hit its goals of delivering consistent high-single-digit EPS growth.Medtronic is ramping up several new products, with many more in the pipeline.Medtronic's Transformation: A Turning Point AheadIf Medtronic is ...

Collaboration focuses on the development of two advanced edge AI concepts in anesthesiology and neonatal care designed to help improve patient care. NXP and GE HealthCare Collaborate NXP and GE HealthCare announced a collaboration to pioneer new advancements in edge AI innovation, beginning with new anesthesia and neonatal concepts showcased at CES 2026 LAS VEGAS and CHICAGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ: NXPI) and GE HealthCare (NASDAQ: GEHC) today announced a colla ...

"MDCE leadership engages directly with cutting-edge innovators at CES 2026 as MDCE advances its AI wellness application portfolio." LAS VEGAS, NEVADA / ACCESS Newswire / January 6, 2026 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce that the CEO and members of the Company's tech team are currently attending the Consumer Electronics Show (CES) 2026 in Las Vegas, Nevada. ...

- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect - - Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-center pilot trial for newly diagnosed pancreatic cancer - JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Med ...

Fourth major national payer releases positive comprehensive coverage for AI-powered Heartflow Plaque AnalysisMOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans. Aetna is the fourth major national commercial insurer to upda ...

Good morning. Of all the turnarounds in the past several years, few rival what Larry Culp managed to do for General Electric. Tapped as the first outsider to run GE in late 2018, Culp split the moribund conglomerate into three Fortune 500 public companies: GE HealthCare Technologies, GE Vernova and GE Aerospace. The first to spin off was GE HealthCare, which went public on the Nasdaq exchange on Jan. 4, 2023. Since then, its stock is up almost 50%. (GE Vernova is up 400% since its April 2024 debut, thanks i ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025. Fiscal Year 2026 Second Quarter Highlights Quarter Ended November 30, 2025 Pro Forma* YoY Growth Net Sales $. ...